@FreddyLA7 I am a local photographer and have many photos of the area, including the park. Here is my link. If you see something you like, DM me and I will send you the file so that you can the photo printed at home. Dave
https://t.co/TwQBUkUfdq
Is improving clinical decision-making on your 2025 resolutions list? Volpara Scorecard™ will give your team:
✅ Key breast density and risk insights in one view.
✅ Science-based data and alerts when patients meet high-risk thresholds.
https://t.co/xrC0Kzd8Ur
Over 25% of patients at @RushUniversity Medical Center are flagged as high-risk for breast cancer—thanks to Volpara® Risk Pathways™. In just two years, 69% of high-risk patients met NCCN Guidelines® for follow-up, leading to improved outcomes.
https://t.co/5Q19c8qwpg
In just 24 months, @mySingingRiver achieved:
✔️ 25% of patients met NCCN Guidelines® for genetic testing.
✔️ 36% completed the test onsite, identifying 6% with pathogenic mutations or carrier status.
✔️ 42% received negative genetic results
Learn more: https://t.co/iqZhowS66n
Lunit AI + one radiologist = superior results. 📊 At St Göran Hospital, this combo achieved a Cancer Detection Rate (CDR) of 4.7 per 1000, surpassing the traditional two-radiologist approach with a CDR of 4.5 per 1000.
Read the study here 👉 https://t.co/blEu4HXcvD
AI in breast imaging offers clinical and operational benefits. In the final installment of our breast density series, we cover how AI reduces medicolegal risks, supports radiologists facing staffing shortages, and ensures consistent, accurate assessments.
https://t.co/jQWdYGhY4O
At @mySingingRiver, every patient’s cancer risk is calculated using the Tyrer-Cuzick v8 (TC8) risk model and NCCN Guidelines® within Volpara Risk Pathways®—ensuring no one slips through the cracks, especially in their diverse, high-risk population.
https://t.co/iqZhowS66n
“Our patients receive so much more than a mammogram. We help them understand their complete risk level and how to mitigate that risk with clinically proven strategies.” – Dr. Lisa Stempel, Division Chief of Breast Imaging at @RushMedical
https://t.co/5Q19c8qwpg
On #WorldDenseBreastDay, our CEO Teri Thomas was featured by @OncoZine, explaining how dense breast tissue impacts early detection and why supplemental screening is essential.
Learn more: https://t.co/g2u4ZsGhWi
#womenshealth#breastcancer
“I wondered how Volpara could distinguish differences between our old and new system and was impressed to learn that Volpara tests their AI software on every mammography manufacturer’s machines.”
Learn more: https://t.co/oc8SLlbYSg
@hotelsdotcom
I have been a customer for 13 years and have seen your customer service become terrible. I am no longer using you as of today. I sent in an email if you really care. I am not holding my breath.
🚨 The FDA's new mammogram guidelines will help women better understand their breast density—a key factor in cancer detection. Honored to share our perspective in USA Today. As our CEO Teri Thomas said, “It’s like looking for a snowball in a field of snow.” Proud to support the #FindItEarlyAct.
https://t.co/CUB56GureE
#BreastHealth #EarlyDetection
⭐ “I was very proud. It was so helpful starting out with Volpara Analytics and receiving so much feedback. I wish I had access to this tool in school.”
Discover how Volpara Analytics™ helps techs feel more confident and maintain (or improve) quality: https://t.co/wUmzFzrb7u
Thank you @RepSherrill for cosponsorship of the Find It Early Act to ensure all health insurance plans cover breast imaging if needed after a mammogram with no out-of-pocket costs. It will save lives. Thanks, too, to New Jersey state advocates Laurie Scofield and Beverly Baeder.